Table 3.
Pharmacokinetic parameters for paclitaxel in plasma after intravenous administration of free PTX, CL-PTX, and TL-PTX (mean ± standard deviation)
| Parameters | Units | Free-PTX | CL-PTX | TL-PTX |
|---|---|---|---|---|
| T1/2 | h | 8.562 ± 0.11 | 14.476 ± 0.07 | 29.122 ± 0.11 |
| Tmax | h | 0.5 ± 0.00 | 0.5 ± 0.00 | 0.5 ± 0.00 |
| Cmax | mg L−1 | 5.58 ± 0.31 | 7.93 ± 0.47 | 18.95 ± 1.03* |
| AUC0>t | mg L−1 h | 26.9 ± 1.97 | 39.9 ± 2.67 | 62.17 ± 4.72* |
| AUC0→∝ | mg L−1 h | 30.01 ± 2.96 | 52.98 ± 2.49 | 120.00 ± 6.92* |
| AUMC0→∝ | 160.89 ± 7.15 | 281.93 ± 12.29 | 480.57 ± 16.92* | |
| MRT0→∝ | h | 9.15 ± 0.27 | 16.42 ± 0.36 | 3.50 ± 0.93 |
| Vd | L kg−1 | 4.12 ± 0.04 | 3.94 ± 0.08 | 3.50 ± 0.02 |
| CL | L h−1 kg−1 | 0.33 ± 0.03 | 0.19 ± 0.04 | 0.08 ± 0.06* |
Notes: Each data was from five mice.
*
P values ≤ 0.05 were considered to be statistically significant compared with the free PTX group.
Abbreviations: CL-PTX, paclitaxel-loaded conventional liposomes; TL-PTX, paclitaxel-loaded targeted PEGylated liposomes; Free PTX, paclitaxel dissolved in Cremophor EL; Tmax, time to maximum plasma concentration of drug; Cmax, maximum plasma concentration of drug; T1/2, elimination half life; CL, clearance; MRT, mean residence time; Vd, apparent volume of distribution; AUC0→∝, area under the plasma concentration-time curve.